Oral nuvisertib for myelofibrosis after JAK inhibitor failure
Treatments studied
Part of Blood & lymphatic clinical trials.
This early-phase study tests whether an oral medicine called nuvisertib (TP-3654) can improve symptoms and disease control in people with myelofibrosis, including those who did not respond well to JAK inhibitors. Some participants may also receive nuvisertib with other JAK-related medicines to see which approach works best.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have myelofibrosis: primary myelofibrosis or post–PV/ET myelofibrosis, and it’s intermediate- or high-risk
- You previously tried a JAK inhibitor (like ruxolitinib) and either couldn’t tolerate it, it didn’t work, or you can’t take JAK inhibitors (depending on study arm)
- Your blood counts are high enough for treatment (platelets and a type of white blood cell called ANC), and there are less than 5% blasts in blood
- Your energy/activity level is fairly good (ECOG 0–1), and you’re expected to live at least 6 months
- You have an enlarged spleen (measured by CT or MRI as spleen volume ≥450 cm³) within about 2 weeks before starting
- Your symptom burden on the myelofibrosis symptom scale (MF-SAF) meets the study’s minimum score for that treatment arm
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding TL-895 to ruxolitinib can improve outcomes in adults with myelofibrosis. It focuses on people who are not getting enough benefit from ruxolitinib or who need treatment as part of the study.
This trial tests a new drug called Navtemadlin when added to the standard treatment ruxolitinib for people with myelofibrosis who are not getting the best results from ruxolitinib alone. It may help improve response and control the disease.
This trial tests a new drug called RVU120 for people with myelofibrosis that has not responded well to standard JAK inhibitor treatment. It aims to shrink the spleen and improve symptoms.
This study tests an experimental drug called revumenib, either alone or combined with a JAK inhibitor, for people with myelofibrosis that is still active despite standard treatment. The goal is to see if revumenib can better control symptoms, reduce spleen size, or improve blood counts.
This trial tests a new combination of two drugs, ruxolitinib and ulixertinib, for people with myelofibrosis whose disease is not fully controlled by ruxolitinib alone. The goal is to see if adding ulixertinib can improve spleen enlargement, symptoms, or bone marrow changes.
This trial tests an experimental drug called PMD-026 for people with myelofibrosis that has not responded well to a JAK inhibitor (like ruxolitinib). The goal is to see if PMD-026 can help reduce symptoms and spleen size.
Hear when a new Myelofibrosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.